Aramark (0AK) News

Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series

Live webcast on Wednesday, July 24th at 4:00 PM ET THE WOODLANDS, TX, July 22, 2024 (GLOBE NEWSWIRE...

Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment Covering Technology License Agreement

Brad Hauser, Chief Executive Officer of Autonomix, discusses the Company’s agreement to license FDA-cleared...

Autonomix Enters into Definitive Agreement to License Intellectual Property for FDA-Cleared Ablation Technology from RF Innovations, Inc.

RF Innovations’ Apex 6 Generator aligns with specifications required for Autonomix’s ablation system and...

Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Launch of CEO Corner Platform

CEO Corner segments to include additional discussion related to press releases, events, corporate updates and...

Autonomix Medical, Inc. (NASDAQ: AMIX) Reviews Positive Results Seen in Pancreatic Cancer Pain Trial in Virtual Investor “What This Means” Segment

Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses preliminary positive results from the first...

Form 8-K - Current report

Autonomix Announces Positive Topline Results from First Five Lead-In Patients in Ongoing Human Clinical Trial

The first five patients successfully completed protocols with no immediate procedural-related complications or...

Form 8-K - Current report

Autonomix Enhances Executive Leadership Team with Appointment of Proven Medical Technology Leader, Brad Hauser, as President and Chief Executive Officer

Former President and Chief Executive Officer, Lori Bisson, appointed as Executive Vice Chairman THE WOODLANDS...

Autonomix to Announce Preliminary Topline Results from First Five Lead-In Patients in Ongoing Human Clinical Trial on June 18, 2024

Management to host live webcast to discuss results on Tuesday, June 18th at 8:30 a.m. ET THE WOODLANDS, TX...

Autonomix Announces Approval of Protocol Amendment by Ethics Committee Upon Completion of All Lead-In Patients in Ongoing Human Clinical Trial

Company plans to release topline results from “lead-in” patients (n=5) imminently THE WOODLANDS, TX, June 03...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Autonomix Medical, Inc. Reports Full Year 2024 Financial Results and Provides Corporate Update

Year marked by operational and clinical execution advancing the development of a potential breakthrough...